First product launch in USA for Acacia Pharma

24 August 2020

Barhemsys (amisulpride injection), a novel product for the prevention and treatment of post-operative nausea and vomiting (PONV), has launched in the USA.

The first product from UK drugmaker Acacia Pharma (Euronext: ACPH), Barhemsys was approved by the US Food and Drug Administration in February 2020. Shares in the company were lifted 5% in Monday morning trading.

The firm’s second product, Byfavo (remimazolam injection), was approved in early July. In-licensed from Italy’s Cosmo Pharmaceuticals, the therapy is currently under review by the Drug Enforcement Administration and will need to be scheduled under the Controlled Substances Act before it can be marketed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK